Home » EMA Calls Trial Data Transparency Draft Policy Balanced and Fair
EMA Calls Trial Data Transparency Draft Policy Balanced and Fair
June 27, 2014
The European Medicines Agency is pushing back against critics who accuse it of softening its commitment to clinical trials data transparency, saying there has been “absolutely no change in direction” in the agency’s efforts to make trial data more publicly available.
To View This Article:
Subscribe To International Pharmaceutical Regulatory Monitor